This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): trandolapril, Gopten, Odrik
Description: Trandolapril is the ethyl ester prodrug of a nonsulfhydryl angiotensin converting enzyme (ACE) inhibitor, trandolaprilat. Trandolapril is deesterdified to trandolaprilat, which is approximately eight times more active as an inhibitor of ACE activity.
ACE catalyzes the conversion of angiotensin I to the vasoconstrictor, angiotensin II. The effect of trandolapril in hypertension appears to result primarily from the inhibition of ciruclating and tissue ACE activity, thereby decreasing vasoconstriction, decreasing aldosterone secretion, and increasing plasma renin.
Abbott and Sanofi
In June 2004, Abbott Laboratories and Aventis reached an agreement for Abbott to acquire the remaining commercial rights for the cardiovascular agents trandolapril and the trandolapril/verapamil combination, except in Japan, and the global manufacturing rights fortrandolapril and the trandolapril/verapamil combination. Under the terms of the agreement, Aventis will receive an upfront payment as well as milestone payments, totaling $300 million U.S. Additionally, Aventis will receive royalties on future sales.
Abbott and AbbVie
In October 2011, Abbott announced plans to separate into two publicly traded companies, one in diversified medical products and the other in research-based pharmaceuticals. The diversified medical products company will consist of Abbott's existing diversified medical products portfolio, including its branded generic pharmaceutical, devices, diagnostic and nutritional businesses, and will retain the Abbott name....See full deal structure in Biomedtracker
Partners: Sanofi Abbott Laboratories
Pink Sheet In Brief: Knoll's Mavik
Pink Sheet Knoll Mavik and Tarka
Additional information available to subscribers only: